 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Precipio announces 1-for-20 reverse stock split

Company announces 1-for-20 reverse stock splitNEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has...

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Company continues to make strides towards profitabilityNEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its...

Precipio s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript

Conference Call to be held on August 17, 2023 at 5:00 PM ESTNEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics companyPrecipio, Inc.(NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET. The call will include updates on all of ...

Precipio Announces Q2-2023 Shareholder Update Call

Precipio launches quantitative BCR-ABL 2.0 panel for patients with chronic myeloid leukemia

Advanced panel already generating six-figure pre-ordersNEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind...

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

These efficiencies plus revenue growth expected to continue the positive momentumNEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces significant reductions in its cash-burn. For the six months ended June 30, 2023, Precipio...

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Revenue growth and customer pipeline advance the Company towards breakevenNEW HAVEN, Conn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q2-2023 revenues have increased to $3.5M in Q2-2023 from $2.8M in Q1-2023, an increase of ...

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Precipio (NASDAQ:PRPO Free Report) and ProPhase Labs (NASDAQ:PRPH Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst ...

Head-To-Head Comparison: Precipio (NASDAQ:PRPO) and ProPhase Labs (NASDAQ:PRPH)

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Watchers	30,797
52-Wk Low	$0.28
52-Wk High	$1.02

Market Cap	$8.16M
Volume (M)	816,018.00
52-Wk High	$1.02
52-Wk Low	$0.28

PRPO Precipio Inc

About

Feed

News

Sentiment

Fundamentals